Inventiva announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development and Chief Medical Officer. Dr. Campagna brings extensive expertise in the MASH field, having previously served as CMO at Q32 Bio and MASH Global Program Lead at Intercept Pharmaceuticals.
Martine Zimmermann, PharmD, was appointed Executive Vice President of Regulatory Affairs and Quality Assurance. Dr. Zimmermann's experience includes leading regulatory approvals for liver disease drugs at Ipsen, including a dual PPARα/δ agonist, and senior roles at Alexion Pharma.
These appointments are strategic moves to strengthen Inventiva's executive leadership team as the company prepares for the readout of its NATiV3 Phase 3 study next year and the potential regulatory approval and commercialization of lanifibranor. Dr. Campagna succeeds co-founder Pierre Broqua, who transitions to a Scientific Advisor role, and Michael Cooreman, who departs as CMO.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.